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Plasma triglyceride concentration is a biomarker for circulating triglyceride-rich lipoproteins and their metabolic 
remnants. Common mild-to-moderate hypertriglyceridaemia is typically multigenic, and results from the cumulative 
burden of common and rare variants in more than 30 genes, as quantiﬁ ed by genetic risk scores. Rare autosomal 
recessive monogenic hypertriglyceridaemia can result from large-eﬀ ect mutations in six diﬀ erent genes. 
Hypertriglyceridaemia is exacerbated by non-genetic factors. On the basis of recent genetic data, we redeﬁ ne the 
disorder into two states: severe (triglyceride concentration >10 mmol/L), which is more likely to have a monogenic 
cause; and mild-to-moderate (triglyceride concentration 2–10 mmol/L). Because of clustering of susceptibility alleles 
and secondary factors in families, biochemical screening and counselling for family members is essential, but routine 
genetic testing is not warranted. Treatment includes management of lifestyle and secondary factors, and 
pharmacotherapy. In severe hypertriglyceridaemia, intervention is indicated because of pancreatitis risk; in mild-to-
moderate hypertriglyceridaemia, intervention can be indicated to prevent cardiovascular disease, dependent on 
triglyceride concentration, concomitant lipoprotein disturbances, and overall cardiovascular risk.
Introduction
The complex causes and classiﬁ cation of hyper tri-
glyceridaemia frequently make diagnosis and manage-
ment a challenge to many clinicians of diverse specialties. 
Hyper triglyceridaemia is usually diagnosed when the 
fasting plasma concentration of triglyceride exceeds a 
threshold value (eg, >1·7 mmol/L [>150 mg/dL]). Severe 
hypertriglyceridaemia is often diagnosed when plasma 
triglyceride concentration is >10 mmol/L (>885 mg/dL).1–7 
Proposed deﬁ nitions of hyper tri glyceridaemia vary 
(table 1), and none predominates in clinical use. 
Traditional classiﬁ cation schemes for hypertri-
glyceridaemia have used terms such as familial hypertri-
glyceridaemia and familial combined hyperlipidaemia, 
which imply a single gene or monogenic cause. However, 
most cases of hyper triglyceridaemia are the result of 
many genetic factors—ie, they are multigenic or 
polygenic, with accumulations of both common DNA 
variants with small eﬀ ect size, and rare DNA variants 
with large eﬀ ect size.4 Hyper triglyceridaemia in 
susceptible individuals is further exacerbated by exposure 
to non-genetic secondary factors,4 including lifestyle 
factors such as being over weight and alcohol use.
Although prospective and case-control studies have 
identiﬁ ed high plasma concentration of triglyceride as 
an independent risk factor for cardiovascular disease,8,9 
uncertainty remains about the speciﬁ c role of 
triglyceride-rich lipoproteins in atherogenesis.1–3 
Furthermore, ﬁ ndings from intervention studies aimed 
at reducing triglyceride concentrations have shown 
inconsistent eﬀ ects for cardiovascular disease outcomes, 
and no eﬀ ect on stroke and all-cause mortality.3 
Therefore, mild-to-moderate hypertriglyceridaemia is 
often viewed as a mere marker of cardiovascular disease 
risk, whereas severe hypertriglyceridaemia remains a 
well known risk factor for acute pancreatitis.4 Although 
the need to intervene in an individual with severe hyper-
triglyceridaemia is un disputed, the appropriate response 
for mild-to-moderate hypertriglyceridaemia is less clear. 
In this Review, we recommend redeﬁ nition of hyper tri-
glyceridaemia using a two-group classiﬁ cation to 
simplify the diagnosis and clinical management of 
hyper tri glyceridaemia states.
Plasma triglyceride 
concentration 
(mmol/L)
2011 ESC/EAS guidelines6,7
Normal <1·7
Hypertriglyceridaemia 1·7–9·9
Severe hypertriglyceridaemia ≥10
2001 NCEP ATP III guidelines5
Normal <1·7
Hypertriglyceridaemia
Borderline high 1·7–2·3
High 2·3–5·6
Very high >5·6
2012 Endocrine Society guidelines1
Normal <1·7
Hypertriglyceridaemia
Mild 1·7–2·3
Moderate 2·3–11·2
Severe hypertriglyceridaemia
Severe 11·2–22·4
Very severe >22·4
ESC=European Society of Cardiology. EAS=European Atherosclerosis Society. 
NCEP ATP III=National Cholesterol Education Program Adult Treatment Panel III.
Table 1: Clinical deﬁ nitions for hypertriglyceridaemia
Lancet Diabetes Endocrinol 2013 
Published Online
December 23, 2013
http://dx.doi.org/10.1016/
S2213-8587(13)70191-8
Department of Medicine, 
Western University, London, 
ON, Canada 
(Prof R A Hegele MD); Irving 
Institute for Clinical and 
Translational Research, 
Columbia University, New York, 
NY, USA (Prof H N Ginsberg MD); 
Dyslipidaemia and 
Atherosclerosis Research Unit, 
INSERM U939, Pitié-Salpêtrière 
University Hospital, Paris, 
France (Prof M J Chapman DSc); 
Department of Diagnostic 
Sciences, Herlev Hospital, 
University of Copenhagen, 
Denmark 
(Prof B G Nordestgaard DMSc); 
Department of Molecular 
Genetics, University Medical 
Center Groningen, University of 
Groningen, Netherlands 
(J A Kuivenhoven PhD); 
Department of Internal 
Medicine, University of 
Palermo, Palermo, Italy 
(Prof M Averna MD); Strategic 
Research Center, Sahlgrenska 
Center for Cardiovascular and 
Metabolic Research, University 
of Gothenburg, Gothenburg, 
Sweden (Prof J Borén PhD); 
Department of Endocrinology 
and Metabolism, 
Endocrinology and 
Cardiovascular Disease 
Prevention, Hôpital Pitié-
Salpêtrière, Paris, France 
(Prof E Bruckert MD); 
Department of 
Pharmacological Sciences, 
University of Milan and 
Multimedica IRCSS, Milan, Italy 
(Prof A L Catapano PhD); Centre 
de Recherche Médicale, Lipid 
Clinic, Hopital de Jolimont, 
Haine Saint-Paul, Belgium 
(O S Descamps PhD); 
Department of Vascular 
Medicine, Academic Medical 
Center, University of 
Amsterdam, Amsterdam, 
Netherlands (G K Hovingh PhD, 
Prof E Stroes MD); Centre for 
2 www.thelancet.com/diabetes-endocrinology   Published online December 23, 2013   http://dx.doi.org/10.1016/S2213-8587(13)70191-8
Review
Cardiovascular Genetics, 
Institute of Cardiovascular 
Science, University College 
London, London, UK 
(Prof S E Humphries PhD); 
Wihuri Research Institute, 
Helsinki, Finland 
(Prof P T Kovanen MD); Vascular 
Medicine and Metabolism Unit, 
Sant Joan University Hospital, 
Universitat Rovira & Virgili, 
IISPV, CIBERDEM, Reus, Spain 
(Prof L Masana PhD); 
Department of Human 
Genetics, David Geﬀ en School 
of Medicine, University of 
California, Los Angeles, CA, USA 
(P Pajukanta PhD); Department 
of Endocrinology and 
Metabolism, University of 
Munich, Munich, Germany 
(Prof K G Parhofer MD); Division 
of Endocrinology and 
Metabolism, Director of the 
Carbohydrate and Lipid 
Metabolism Research Unit, 
University of the 
Witwatersrand, Johannesburg, 
South Africa (Prof F J Raal PhD); 
Cardiovascular Sciences 
Research Centre, St George’s 
Hospital NHS Trust, London, UK 
(Prof K K Ray MD); Lipid Clinic 
Heart Institute (InCor), 
University of São Paulo Medical 
School Hospital, São Paulo, 
Brazil (R D Santos PhD); 
Department of Internal 
Medicine, Radboud University 
Medical Center, Nijmegen, 
Netherlands 
(Prof A F H Stalenhoef PhD); 
Cardiovascular Research Group, 
Heart and Lung Centre, Helsinki 
University Central Hospital and 
Research Programs Unit, 
Diabetes and Obesity, 
University of Helsinki, Helsinki, 
Finland (Prof M-R Taskinen PhD); 
Department of Clinical 
Biochemistry, Rigshospitalet, 
University of Copenhagen, 
Copenhagen, Denmark 
(Prof A Tybjærg-Hansen DMSc); 
School of Medicine and 
Pharmacology, Royal Perth 
Hospital Unit, The University of 
Western Australia, Perth, WA, 
Australia (Prof G F Watts DSc); 
and Department of Cardiology, 
Wallenberg Laboratory, 
Sahlgrenska University 
Hospital, Gothenburg, Sweden 
(Prof O Wiklund PhD) 
Correspondence to:
Prof Robert A Hegele, Blackburn 
Cardiovascular Genetics 
Laboratory, Robarts Research 
Institute, London, ON, Canada 
N6A 5K8
hegele@robarts.ca
Considerations for measurement of triglyceride 
concentrations
In most countries, triglyceride concentration is 
established by direct laboratory analysis of plasma 
(usually) or serum after a 10–12 h fasting period. Indeed, 
clinicians routinely measure plasma triglyceride, because 
it is usually required for the Friedewald calculation of 
LDL cholesterol concentration. Modern methods for 
measurement of plasma triglyceride establish the free 
glycerol concentration after speciﬁ c lipase action, which 
is the sum of the glycerol formed from the triglyceride 
plus the original free glycerol. However, the value for free 
glycerol is usually ignored because of the low plasma 
concentration of this molecule. Therefore, hyper-
triglyceridaemia can be incorrectly diagnosed in rare 
patients with glycerol kinase deﬁ ciency who have high 
baseline concentrations of plasma glycerol.10 The only 
procedure that reliably diﬀ erentiates the speciﬁ c 
triglyceride-rich lipoprotein fractions is ultracentri-
fugation followed by electrophoresis, which is done in 
some specialised lipid centres.
Most people—certainly in high-income countries—are 
in the non-fasting or postprandial state for most of the 
day. Although recent guidelines1–3,5–7 unequivocally 
recommend measurement of fasting triglyceride 
concentrations, the importance of measurement of non-
fasting triglyceride and remnant cholesterol is an 
emerging aspect of stratiﬁ cation for cardiovascular disease 
risk, because these measures partly show the capacity of 
the individual to clear postprandial lipids. Findings from 
population studies show that despite postprandial 
increases in triglyceride, quantitative changes in other 
lipids, lipoproteins, and apolipoproteins seem to be 
negligible in response to the average meal intake in most 
individuals.11,12 By contrast, for patients with dyslipidaemia 
with or without insulin resistance, the postprandial area 
under the curve for triglyceride-rich lipoproteins can be 
up to four times larger than for patients without 
dyslipidaemia, with pronounced modiﬁ cation of 
lipoprotein remodelling leading to an increase in the 
potentially atherogenic cholesterol load.12
High concentration of non-fasting triglyceride is also 
strongly associated with increased risk of myocardial 
infarction, ischaemic stroke, and early death.13,14 Evidence 
suggests that non-fasting triglyceride-rich lipoproteins or 
their remnants predispose to ischaemic heart disease and 
myocardial infarction.15,16 Non-fasting concentrations of 
total cholesterol, triglyceride, HDL cholesterol, non-HDL 
cholesterol, LDL cholesterol, APOB, APOA1, the ratio of 
total cholesterol to HDL cholesterol, and the ratio of 
APOB to APOA1, are also associated with increased risk 
of cardiovascular disease.11 These ﬁ ndings suggest that, 
compared with proﬁ les for fasting lipids, proﬁ les for non-
fasting lipids are not only useful but also perhaps equally 
or more informative for risk prediction of cardiovascular 
disease. This approach has already been used clinically in 
some Scandinavian countries (eg, Denmark).17
Triglycerides and risk of cardiovascular disease
High plasma concentrations of triglyceride and 
triglyceride-rich lipoproteins have a role in cardiovascular 
disease.1–3 The magnitude of the contribution of triglyceride 
to cardiovascular disease risk and the exact mechanisms 
by which triglyceride-rich lipoproteins exert their eﬀ ects 
on the vascular wall are incompletely established. That 
non-fasting triglyceride concentrations are relevant to 
cardiovascular disease risk is evident from large, long-term 
prospective studies13,18 in the general population, thereby 
corroborating the original hypothesis proposed by 
Zilversmit19 that atherosclerosis, at least partly, occurs 
postprandially. Indeed, triglyceride-rich lipoproteins (eg, 
intermediate-density lipoprotein and very low-density 
lipoprotein) could be particularly prone to entrapment 
within the arterial wall, whereas nascent chylomicrons and 
very large particles of very low-density lipoprotein are too 
large to penetrate.19–23 Consistent with this notion, ﬁ ndings 
from Mendelian randomisation studies suggest that 
lifelong high plasma concentrations of triglyceride-rich 
lipoproteins or their remnants are causally associated with 
increased risk of ischaemic heart disease,15,16 independent 
of subnormal concentrations of HDL cholesterol.13
The relative risk of cardiovascular disease from an 
increase of 1 mmol/L in plasma triglyceride concentrations 
ranges from 1·14 to 1·80, dependent on sex and race, after 
adjustment for established risk factors (eg, HDL 
cholesterol).3 Other studies in various cohorts compared 
the top versus the bottom tertile or quintile for triglyceride 
concentrations, and reported adjusted odds ratios (ORs) of 
1·2–4·0 for increased risk of cardiovascular disease.2 
The  Emerging Risk Factors Collaboration24 assessed 
302 430 people from Europe and North America without 
cardiovascular disease at baseline in 68 prospective 
studies. The hazard ratio (HR) for cardiovascular disease 
was 1·37 per standard deviation of triglyceride (95% CI 
1·31–1·42), after adjustment for non-lipid risk factors. 
However, this risk was essentially lost after adjustment for 
both HDL and non-HDL cholesterol (HR 0·99, 95% CI 
0·94–1·05);24 HDL cholesterol alone weakened, but did 
not abolish, the association (Ray KK, unpublished). 
Importantly, even for non-fasting samples, triglyceride 
was not independently associated with cardiovascular 
disease risk after adjustment for non-HDL cholesterol and 
HDL cholesterol. Although this ﬁ nding suggests that 
HDL cholesterol drives the association with cardiovascular 
disease, re-examination of the putative atheroprotective 
role of HDL25 suggests that triglyceride-related 
mechanisms should be reconsidered as part of the 
pathophysiology of cardiovascular disease. Finally, 
ﬁ ndings from Mendelian randomisation analyses suggest 
a fairly direct causal association between triglyceride and 
triglyceride-rich lipoproteins, and risk of coronary heart 
disease, with similar ORs to those reported for prospective 
studies.15,16,26 Findings from a recent genetic study27 that 
accounted for eﬀ ects on multiple components of the lipid 
proﬁ le similarly supported a causal role for triglycerides in 
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development of coronary artery disease. On the basis of 
the available epidemiological and genetic data, a 
randomised clinical trial of a speciﬁ c triglyceride-lowering 
drug should show a causal association between plasma 
triglyceride concentrations and morbidity and mortality 
from cardiovascular disease. However, ﬁ ndings from 
clinical trials of available drugs to reduce plasma 
triglycerides, which also aﬀ ect other components of the 
lipid proﬁ le, have shown little eﬀ ect for cardiovascular 
disease outcomes.28–31 One reason for this ﬁ nding might 
be that trials with cardiovascular outcomes have mainly 
enrolled individuals without clinically relevant 
hypertriglyceridaemia, making the assessment of the 
eﬀ ects of speciﬁ c interventions challenging.
Historical classiﬁ cation of hypertriglyceridaemia 
phenotypes
Phenotypic heterogeneity among patients with 
hypertriglyceridaemia was deﬁ ned in the past by qualitative 
and quantitative diﬀ erences in plasma lipoproteins. In the 
pre-genomic era, the Fredrickson classiﬁ cation of 
hyperlipoproteinaemia phenotypes (included in the WHO 
International Classiﬁ cation of Diseases32) was based on the 
electrophoretic patterns of lipoprotein fractions (table 2). 
Five of the six phenotypes described by this classiﬁ cation 
include hyper triglyceridaemia in their deﬁ nitions, the only 
exception being familial hypercholesterolaemia (hyper-
lipo proteinaemia type 2A).33,34
The diﬀ erent hypertriglyceridaemia-associated pheno-
types are deﬁ ned by the speciﬁ c class or classes of 
accumulated triglyceride-rich lipoprotein particles, 
including chylomicrons, and very low-density lipoproteins 
and their remnants (table 2).33 Often, excess of triglyceride-
rich lipoproteins coexists with other lipoprotein 
disturbances; for instance, patients with all forms of 
hypertriglyceridaemia often have decreased concentrations 
of HDL cholesterol. Implicit in this classiﬁ cation system 
was the idea that diﬀ erences between hyper-
triglyceridaemia-associated phenotypes were due to 
genetic diﬀ erences; however, recent data suggest that this 
scenario is typically not the case.35–39 As a result, this 
classiﬁ cation system has neither improved scientiﬁ c 
insight nor been clinically useful to direct therapy or 
predict hard outcomes (eg, cardiovascular mortality). We 
suggest that triglyceride concentration itself (ﬁ gure 1), 
together with the presence of other risk factors, should be 
the main driver of clinical management.
Complex genetic basis for hypertriglyceridaemia
For several decades, the word familial has been used in the 
deﬁ nitions and classiﬁ cation of disorders of plasma 
triglyceride metabolism. However, the constant re-
inforcement of this terminology has a misleading eﬀ ect. 
Colloquially, familial often implies a single-gene problem, 
as in the case of familial hypercholesterolaemia, a 
monogenic disorder characterised by increased 
concentrations of LDL cholesterol, xanthelasma 
palpebrarum, arcus cornealis, tendon xanthomata, and 
accelerated atherosclerosis.34 Familial hyperchol ester-
olaemia is usually due to loss-of-function mutations in 
LDLR, which encodes the LDL receptor, and in other genes 
encoding proteins that interact with LDLR such as APOB 
or PCSK9. A clear monogenic cause can be established in 
more than 80% of patients with a strong clinical diagnosis 
of familial hypercholesterolaemia, whereas in the 
remainder, high LDL cholesterol is a polygenic trait due to 
WHO ICD 
number
Fredrickson hyper-
lipoproteinaemia 
phenotype
OMIM number Main lipid change Primary 
lipoprotein 
change
Genetics
Familial hyperchylomicronaemia E78.3 Type 1 238600 ↑Triglyceride ↑Chylomicrons Monogenic; autosomal recessive due to two mutant alleles of 
LPL, APOC2, APOA5, LMF1, GPIHBP1, or GPD1; presentation 
mainly paediatric or early adulthood
Familial hypercholesterolaemia E78.0 Type 2A 143890 ↑Total cholesterol ↑LDL Monogenic; autosomal codominant; heterozygous form results 
from one mutant allele of LDLR, APOB, or PCSK9; homozygous 
form results from two mutant alleles of these genes or of LDLRAP1
Combined 
hyperlipoproteinaemia
E78.2, 
E78.4
Type 2B 144250 ↑Total cholesterol, 
↑triglyceride
↑VLDL,
↑LDL
Polygenic; high GRS for hypertriglyceridaemia; excess of rare 
variants in hypertriglyceridaemia-associated genes; high GRS for 
LDL cholesterol
Dysbetalipoproteinaemia E78.2 Type 3 107741 ↑Total cholesterol, 
↑triglyceride
↑IDL Polygenic; high GRS for hypertriglyceridaemia; excess of rare 
variants in hypertriglyceridaemia-associated genes; APOE ε2/ε2 
homozygosity, or heterozygous rare mutation in APOE
Primary or simple 
hypertriglyceridaemia
E78.1 Type 4 144600 and 
145750
↑Triglyceride ↑VLDL Polygenic; high GRS for hypertriglyceridaemia; excess of rare 
variants in hypertriglyceridaemia-associated genes
Mixed hypertriglyceridaemia E78.3 Type 5 144650 ↑Total cholesterol, 
↑triglyceride
↑VLDL, 
↑chylomicrons
Polygenic; high GRS for hypertriglyceridaemia; excess of rare 
variants in hypertriglyceridaemia-associated genes, with higher 
burden of risk alleles than for hyperlipoproteinaemia type 4
GRS was created by unweighted tallying of risk alleles from single nucleotide polymorphisms associated with increased plasma concentrations of triglyceride and hypertriglyceridaemia. Adapted from Hegele 
(2009).33 ICD=International Classiﬁ cation of Diseases. OMIM=Online Mendelian Inheritance in Man database. VLDL=very low-density lipoprotein. GRS=polygenic genetic risk score. IDL=intermediate-density 
lipoprotiein.
Table 2: Summary of classic hyperlipoproteinaemia phenotypes
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an increased burden of common risk variants.41 By stark 
contrast, more than 95% of patients with hyper trigly-
ceridaemia have a multigenic susceptibility component.3,35–39
Multigenic hypertriglyceridaemia has a complex cause, 
consisting of an excess burden of common small-eﬀ ect 
variants (appendix), in addition to rare heterozygous large-
eﬀ ect variants in genes either directly or indirectly 
associated with plasma triglyceride concentration. Familial 
should not be thought of as synonymous with monogenic; 
most cases of hypertriglyceridaemia are familial or 
inherited, but they are not monogenic.35,36
Monogenic hypertriglyceridaemia
Monogenic hypertriglyceridaemia in patients with severe 
hypertriglyceridaemia (triglyceride concentrations 
>10 mmol/L) displays classic autosomal recessive 
inheritance, with a population prevalence of about one in 
1 000 000. Typically, the disorder is ﬁ rst evident in childhood 
and adolescence. Aﬀ ected individuals are often 
homozygous or compound heterozygous for large-eﬀ ect 
loss-of-function mutations in genes that regulate 
catabolism of triglyceride-rich lipoproteins (eg, LPL, 
APOC2, APOA5, LMF1, GPIHBP1, and GPD1; table 2).37–39 
Patients with monogenic disorders have substantially 
increased fasting concentrations of chylomicrons, but 
usually do not develop premature atherosclerosis, probably 
because of size exclusion that limits the ability of 
chylomicrons to traverse the vascular endothelial 
barrier.19–23 In the 20th century, a diagnosis of LPL deﬁ ciency 
was established biochemically by the absence of LPL 
activity in plasma obtained after intravenous injection of 
heparin.42 At present, the diagnosis can be made by DNA 
sequence analysis, which shows mutations in both LPL 
alleles causing complete LPL deﬁ ciency; mutations in the 
other genes can also be detected by resequencing.43
Multigenic hypertriglyceridaemia
Role of rare variants
Hypertriglyceridaemia, with or without concomitant 
lipid or lipoprotein disturbances, tends to cluster in 
families. Although hypertriglyceridaemia usually does 
not result from strong single-gene eﬀ ects that show 
Mendelian inheritance, it still has a genetic basis, albeit 
one that is more complex in nature. This complexity was 
suggested by ﬁ ndings from pre-molecular-era family 
studies of obligate heterozygous parents of patients with 
complete LPL or APOC2 deﬁ ciency44,45 and unrelated 
heterozygous carriers of disease-causing mutations from 
the general population.46 These study ﬁ ndings showed 
that heterozygous carriers of disease-causing mutations 
had a very wide range of triglyceride phenotypes, ranging 
from normotriglyceridaemia to severe hypertrigly-
ceridaemia,44–46 probably because of chance co-inheritance 
of diﬀ erent numbers of common triglyceride-raising 
variants. Similarly, triglyceride concentrations range 
from normal to very high in heterozygous carriers of 
APOA5 mutations.47 Overall, mean triglyceride 
concentrations in carriers of the various heterozygous 
mutations are higher than in normal family-based or 
population-based controls, but many mutation carriers 
have normal triglyceride concentrations.
DNA resequencing has shown that individuals with 
triglyceride concentrations of more than 3·3 mmol/L 
(>95th percentile in the USA and Canada) as a group 
have a clinically signiﬁ cantly increased—about 2·5 times 
higher—frequency of rare, heterozygous loss-of-function 
mutation in one of several genes governing triglyceride 
metabolism compared with normotriglyceridaemic 
controls.48,49 Most of these variants have conﬁ rmed loss-
of-function eﬀ ects in vitro or predicted harmful eﬀ ects in 
silico.48,49 Although these rare mutations are strongly 
associated with hypertriglyceridaemia in patient groups, 
they are not necessarily associated with hyper-
triglyceridaemia in individual patients. Even within 
families, carriers of the same mutation show a wide 
range of triglyceride concentrations from normal to 
severe hypertriglyceridaemia, with inconsistent vertical 
transmission of triglyceride concentrations in mutation 
carriers across generations.50 Such ﬁ ndings emphasise 
that hypertriglyceridaemia is not a dominantly inherited 
trait in most families with a hypertriglyceridaemia 
proband.
Role of common variants
Findings from genome-wide association studies of 
hypertriglyceridaemia show that common variants in 
several genes (eg, APOA5, GCKR, LPL, and APOB) are 
• Severe triglycerides increase
• Chylomicronaemia
• Pancreatitis risk
• Increased CVD risk likely
• Mild-to-moderate triglycerides increase
• Increased CVD risk
28%
Multigenic:
LPL, APOA5, GCKR, APOB, LMF1, GPIHBP1,
CREBH1, APOC2, APOE, and small-eﬀect variants
Can be monogenic:
LPL, APOC2, APOA5,
LMF1, GPIHBP1, and GPD1 
0·1%
N
um
be
r o
f p
eo
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e
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Non-fasting plasma triglycerides (mmol/L)
26% 46%
Figure 1: Redeﬁ nition of hypertriglyceridaemic states on the basis of new genetic data
Triglyceride concentrations of more than 10 mmol/L, especially in young patients, are more likely to be due to 
monogenic causes combined with secondary factors, whereas patients with triglyceride concentrations of 
2–10 mmol/L represent a single group, based on the interplay of several genes (both heterozygous mutations of 
large eﬀ ect, and the cumulative burden of small-eﬀ ect variants, causing a high genetic risk score; ﬁ gure 2), 
together with secondary factors. Plasma triglyceride concentrations and approximate population percentages are 
based on data for more than 70 000 adults (>20 years of age) from the Copenhagen General Population Study.40
See Online for appendix
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strongly associated with susceptibility to hyper tri-
glyceridaemia.51 In fact, common variations in 
32 triglyceride-associated genes, identiﬁ ed by the Global 
Lipids Genetics Consortium,37–39 are robustly associated 
with hypertriglyceridaemia; the same loci are also 
associated with small variations in plasma triglyceride 
concentrations within the normal range in healthy 
people (appendix). A genetic risk score, constructed by 
unweighted tallying of carrier status for triglyceride-
raising alleles at the 32 triglyceride-associated loci, was 
on average higher for patients with hypertriglyceridaemia 
than for healthy controls (ﬁ gure 2).36,51 Thus, as for 
mutation-negative patients with familial hyper-
cholesterolaemia and LDL-cholesterol raising variants,41 
an increased burden of triglyceride-raising alleles 
contributes to hypertriglyceridaemia susceptibility.48,49
Common plus rare variants
Hypertriglyceridaemia susceptibility is thus established by 
combinations of common small-eﬀ ect and rare large-eﬀ ect 
variants in genes governing production or catabolism, or 
both, of triglyceride-rich lipoproteins.35–38,48,49 People with 
average triglyceride concentrations could have a balance of 
protective and harmful alleles. On the basis of studies of 
765 individuals for whom nine hypertriglyceridaemia-
associated genes were resequenced, common and rare 
genetic variants together accounted for about 25% of total 
variation (and about 50% of attributable variation) in 
hypertriglyceridaemia susceptibility.44,45 Because of the 
wide range of triglyceride concentrations and severity of 
hypertriglyceridaemia phenotypes within families and 
among carriers of the same genotype, genetic testing is not 
recommended. Finally, the classic Fredrickson phenotypes 
characterised by hypertriglyceridaemia closely resemble 
each other at the genetic level, with similar accumulations 
of common and rare genetic variants despite diﬀ erent 
biochemical phenotypes.33,35–38,48,49 Among these phenotypes, 
hyperlipoproteinaemia type 3 (dysbetalipoproteinaemia) is 
unique in that a single gene (APOE) can force the 
expression of hypertriglyceridaemia and hypercholester-
olaemia because of accumulation of remnant particles; the 
cumulative eﬀ ects of polygenic predisposition are 
compounded by either homozygosity for the binding-
defective E2 isoform of APOE, or heterozygosity for a rare 
dysfunctional APOE mutation.36
Secondary causes
Hypertriglyceridaemia is often associated with other 
disorders that independently increase plasma triglyceride 
concentrations, such as type 2 diabetes, obesity, alcohol 
overuse, hypothyroidism, pregnancy, hepatosteatosis, 
renal failure, or concomitant drug use (panel 1).1,4,6,7 When 
one of these factors is present, hypertriglyceridaemia is 
termed secondary. However, secondary hyper-
triglyceridaemia often also has a genetic component, 
because some secondary factors are frequently, but not 
universally, associated with hypertriglyceridaemia. This 
genetic component suggests that people who develop 
dyslipidaemia might carry inherited defects that confer 
susceptibility, which becomes clinically expressed in the 
presence of an external or secondary stress.4 For example, 
abdominal obesity, metabolic syndrome, and non-
alcoholic fatty liver disease are associated with increased 
risk of hypertriglyceridaemia and are becoming 
increasingly common in adults, adolescents, and even 
children. Whether there is a strong secondary factor 
Figure 2: Genetic risk scores for triglyceride-associated risk alleles
Unweighted risk scores composed of risk alleles at 32 triglyceride-associated loci were summed across individuals 
and compared between patients with hypertriglyceridaemia and controls. The minimum unweighted risk score 
is 0, whereas the maximum unweighted risk score is 64, but most scores in the population range between 22 and 
46. Compared with healthy controls, the relative frequency distribution of triglyceride genetic risk scores was 
signiﬁ cantly increased in 504 patients with hypertriglyceridaemia (p=1·6×10−53). Figure reproduced from Johansen 
and colleagues39 by permission of Elsevier.
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Panel 1: Secondary causes of hypertriglyceridaemia
• Obesity
• Metabolic syndrome
• Diet with high positive energy-intake balance, and high fat 
or high glycaemic index
• Increased alcohol consumption*
• Diabetes (mainly type 2 diabetes)
• Hypothyroidism
• Renal disease (proteinuria, uraemia, or glomerulonephritis)
• Pregnancy (particularly in the third trimester)
• Paraproteinaemia
• Systemic lupus erythematosus
• Drugs including corticosteroids, oral oestrogen, 
tamoxifen, thiazides, non-cardioselective β blockers and 
bile acid sequestrants, cyclophosphamide, asparaginase, 
protease inhibitors, and second-generation antipsychotic 
drugs (eg, clozapine and olanzapine)
*Although the range is variable, clinically the risk of hypertriglyceridaemia is generally 
thought to increase with more than two units daily for men, and more than one unit 
daily for women.
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underlying dyslipidaemia needs to be established, 
because this knowledge would guide intervention. 
Furthermore, the severity of secondary hypertrigly-
ceridaemia in an individual is probably determined by 
their genetic susceptibility component. Finally, some 
secondary causes, such as obesity, metabolic syndrome, 
non-alcoholic fatty liver disease, and diabetes, have their 
own genetic susceptibility components.
Redeﬁ nition of hypertriglyceridaemic states
On the basis of new genetic data, we recommend a 
redeﬁ nition of hypertriglyceridaemia states (panel 2). First, 
triglyceride concentrations of more than 10 mmol/L are 
likely to have a monogenic basis (especially in young 
patients), together with interacting secondary factors. 
However, even in this group, in many instances 
(particularly in adults) no monogenic cause can be 
established; in these cases, there is marked polygenic 
susceptibility compounded by signiﬁ cant exposure to 
secondary factors. Thus, except in children and adolescents 
with severe hypertriglyceridaemia, we do not recommend 
routine genetic testing, even for adults with triglyceride 
concentrations of more than 10 mmol/L. Second, people 
with triglyceride concentrations of 2–10 mmol/L should be 
considered as a single group, irrespective of concomitant 
lipoprotein disturbances (eg, increased LDL cholesterol), 
with increased triglyceride caused by interaction of several 
genetic eﬀ ects and secondary factors (ﬁ gure 1). For 
example, individuals with hyper lipo proteinaemia type 2B 
(often called familial combined hyperlipidaemia; table 2) 
have the same genetic risk score as do individuals with 
similar triglyceride concentrations who have isolated or 
hyperlipoproteinaemia type 4 hypertriglyceridaemia; they 
diﬀ er in that individuals with hyperlipoproteinaemia 
type 2B have a higher genetic burden of alleles associated 
with hypercholesterolaemia.36 Again, we do not 
recommend routine genetic testing in any individuals with 
triglyceride concentrations of 2–10 mmol/L, and 
recommend testing in severe triglyceridaemia only for 
paediatric and adolescent patients.
Desirable concentrations of triglyceride and 
related variables
Hypertriglyceridaemia is arbitrarily deﬁ ned as a plasma 
triglyceride concentration of more than 2 mmol/L 
(>175 mg/dL) on the basis of large prospective 
observational studies, although plasma triglyceride can 
start to confer risk or become a marker for cardiovascular 
disease at even lower concentrations.4,6,7,13,14 Triglyceride 
concentrations rising above this threshold, due to 
increased production or decreased clearance of 
triglyceride-rich lipoproteins from the circulation, are 
accompanied by changes in the metabolism and 
composition of other lipoprotein fractions such as LDL 
and HDL, which might partly explain the increased 
cardiovascular disease risk.3
According to the joint guidelines from the European 
Society of Cardiology and the European Atherosclerosis 
Society for management of dyslipidaemia, and 
Consensus Panel recommendations from the European 
Atherosclerosis Society, a triglyceride concentration of 
less than 1·7 mmol/L (<150 mg/dL) is desirable, 
especially if HDL cholesterol is less than 1·0 mmol/L 
(<40 mg/dL) in men or 1·2 mmol/L (<45 mg/dL) in 
women.3,6,7 In post-hoc subgroup analyses of clinical 
endpoint studies of ﬁ brates, clinical beneﬁ t was shown 
in people with triglyceride concentrations of more than 
2·3 mmol/L (>200 mg/dL) and low HDL cholesterol.28,29 
Thus, when lifestyle measures are insuﬃ  cient, 
individuals with high risk of cardiovascular disease and 
increased plasma triglyceride could be considered for 
drug treatment if triglyceride concentrations exceed 
2·3 mmol/L.3,6,7 However, there is inadequate evidence to 
deﬁ ne treatment targets for plasma triglyceride. Even the 
triglyceride threshold for diagnosis of hyper-
triglyceridaemia is not irrefutable; no high-grade 
evidence exists to suggest that 2·0 mmol/L is better than 
1·7 or 2·3 mmol/L. In this Review, we use 2·0 mmol/L 
as the diagnostic threshold for hypertriglyceridaemia 
(panel 3), but expert opinion suggests values of 
±0·3 mmol/L around this cutpoint.1,3–7
An emerging focus for reduction of cardiovascular 
disease risk in patients with hypertriglyceridaemia is the 
concentration of non-HDL cholesterol (comprising 
cholesterol in LDL and in remnant triglyceride-rich 
lipoproteins), which represents the total mass of 
cholesterol in circulating atherogenic lipoprotein 
particles.3,13,15,16 This variable has been advocated because 
LDL cholesterol cannot be estimated by the Friedewald 
equation when triglyceride concentrations are more 
than 4·5 mmol/L; additionally, standardised direct 
measurement of LDL cholesterol is not routinely 
available in most centres. The desirable concentration of 
non-HDL cholesterol is less than 2·6 mmol/L 
Panel 2: Proposed simpliﬁ ed redeﬁ nition of 
hypertriglyceridaemia
• Normal: triglyceride concentration less than 2·0 mmol/L 
(175 mg/dL)
• Mild-to-moderate: triglyceride concentration between 
2·0 and 10·0 mmol/L (175–885 mg/dL)
• Severe: triglyceride concentration more than 10·0 mmol/L 
(885 mg/dL)
Panel 3: Desirable concentrations of lipids and APOB in 
patients at high risk of cardiovascular disease
• Triglycerides: concentration less than 1·7 mmol/L (150 mg/dL)
• Non-HDL cholesterol: concentration less than 2·6 mmol/L 
(100 mg/dL)
• APOB: concentration less than 0·8 g/L in high-risk patients, 
and less than 0·7 g/L in very high-risk patients
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(<100 mg/dL) in high-risk individuals, and less than 
3·4 mmol/L (<130 mg/dL) in low-risk individuals 
(panel 3). Again, there is insuﬃ  cient high-grade evidence 
to deﬁ ne speciﬁ c targets for any of these alternative 
variables, and treatment should be individually 
tailored.3,6,7
An alternative estimation of atherogenic lipoprotein 
concentrations uses APOB as a substitute for non-HDL 
cholesterol. APOB represents the total number of 
atherogenic APOB-containing lipoprotein particles, and 
predicts cardiovascular disease risk at least as well as 
non-HDL cholesterol.6,7 APOB can be reliably measured 
in the presence of hypertriglyceridaemia and under non-
fasting conditions. Some expert panels have therefore 
recommended APOB as a secondary target in individuals 
with hypertriglyceridaemia.3,6,7,52 Accordingly, APOB 
concentrations of more than 1·2 g/L identify individuals 
at high risk of cardiovascular disease, and the desirable 
concentration is less than 0·8 g/L.3,6,7 For individuals at 
very high risk, an APOB target of less than 0·7 g/L might 
be appropriate, corresponding to a non-HDL cholesterol 
concentration of less than 2·6 mmol/L (100 mg/dL; 
panel 3).3,6,7
Management of hypertriglyceridaemia
Treatment for short-term and long-term risks
Treatment of hypertriglyceridaemia has two distinct 
objectives: immediate prevention of pancreatitis in 
patients with severe hypertriglyceridaemia (triglyceride 
concentration >10 mmol/L), and reduction of global 
cardiovascular disease risk. Because hypertrigly-
ceridaemia is characterised by increased concentrations 
of remnant triglyceride-rich lipoproteins, concentrations 
of non-HDL cholesterol or APOB are secondary 
treatment targets, after LDL cholesterol.53
After secondary causes have been treated, the 
management of mild-to-moderate hypertriglyceridaemia 
should follow guideline recommendations,3,6,7 with initial 
emphasis on diet and exercise. Non-pharmacological 
therapy is recommended for individuals with triglyceride 
concentrations of more than 2 mmol/L. The decision to 
initiate pharmacological therapy depends on the amount 
of triglyceride elevation. Individuals with triglyceride 
concentrations of more than 10 mmol/L warrant 
immediate and aggressive triglyceride reduction to 
minimise the risk of acute pancreatitis, with use of a 
strict fat-reduced diet and avoidance of simple 
carbohydrates; use of ﬁ brates, nicotinic acid, or 
omega-3 fatty acids could also be considered. In the 
context of abdominal pain, treatment of severe hyper tri-
glyceridaemia includes hospitalisation, with cessation of 
oral intake, and supportive measures including ﬂ uid 
replacement, avoidance of glucose infusions, and control 
of obvious precipitating factors (eg, diabetes). Drugs are 
less eﬀ ective in this situation, and substantial 
interventions—eg, infusions of insulin or heparin, high-
dose antioxidants, or plasma exchange—are also 
probably of little value for most patients.4 As noted 
earlier, because of the uncertain clinical beneﬁ t, practice 
guidelines are not universal or consistent regarding the 
management of individuals with triglyceride 
concentrations of 2–10 mmol/L.
Patients with hypertriglyceridaemia should be assessed 
and managed for their global risk of cardiovascular 
disease (table 3), which does not necessarily imply 
management of their triglyceride concentrations. A 
positive family history of cardiovascular disease (deﬁ ned 
as at least one ﬁ rst-degree relative or at least two second-
degree relatives with cardiovascular disease) should be 
taken into account, even if it is independent of 
dyslipidaemia. Because many susceptibility alleles, 
environmental factors, and secondary factors tend to be 
shared within families, other family members might also 
have a lipid disorder and assessment for dyslipidaemia 
and related cardiometabolic risk should be considered. 
This situation is analogous to that for type 2 diabetes, 
which clusters in families but is usually not associated 
with a single monogenic cause.
Moderately high (2–9·9 mmol/L) High (≥10 mmol/L)
Treatment priority Prevent cardiovascular disease Prevent acute pancreatitis
Primary therapeutic goal Achieve LDL cholesterol target Reduce triglyceride concentrations
Secondary therapeutic goals Achieve non-HDL cholesterol target, which is 0·8 mmol/L higher than LDL 
cholesterol goal, or APOB concentration <0·8 g/L; rule out and treat 
secondary factors
Goals: achieve LDL cholesterol and non-HDL cholesterol goals once pancreatitis 
risk is decreased, as described above; rule out and treat secondary factors
Non-pharmacological 
therapeutic strategies
Reduce bodyweight, reduce alcohol intake, reduce simple sugar intake, increase 
aerobic activity, reduce total carbohydrate intake, replace trans and saturated 
fats with monounsaturated fats, increase dietary omega-3 fatty acids
Eliminate oral intake during acute pancreatitis with intravenous rehydration, 
then slowly re-introduce foods with small frequent meals, then longer-term 
strict fat-reduced diet (<20% of calories as fat), reduce bodyweight, reduce 
alcohol intake, reduce simple sugar intake, reduce total carbohydrate intake, 
replace trans and saturated fats with monounsaturated fats; increase dietary 
omega-3 fatty acids; increase aerobic activity
Pharmacological therapeutic 
strategies
Statins if necessary to control LDL cholesterol; if LDL cholesterol is close to 
goal, titrate statin dose to achieve both LDL and non-HDL cholesterol targets; 
if LDL cholesterol is at goal, but non-HDL cholesterol is still high, titrate statin 
dose or add ﬁ brate, nicotinic acid, or omega-3 fatty acids
Consider ﬁ brate, nicotinic acid, and omega-3 fatty acids
Table 3: Treatment strategies for hypertriglyceridaemia by triglyceride concentration
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Increased LDL cholesterol is part of the phenotype of 
combined hyperlipidaemia, and ampliﬁ es cardiovascular 
disease risk. Thus, family members (particularly ﬁ rst-
degree relatives of such patients) should be screened. 
Irrespective of clinical designation, individuals with 
combined hyperlipidaemia in particular, and hyper-
triglyceridaemia in general, still need to be managed. 
Risk assessment and continuing care needs baseline and 
follow-up lipid proﬁ ling, especially because hyper-
triglyceridaemia can obscure calculation of LDL 
cholesterol in these instances. Furthermore, measure-
ments of non-HDL cholesterol (or, if available, APOB) 
concentrations can be helpful for both risk assessment 
and monitoring of treatment if LDL cholesterol 
concentrations cannot be measured.
Statins
Statins decrease LDL cholesterol concentrations by up to 
55%, leading to a reduction in cardiovascular disease risk 
of 23% per mmol/L of LDL cholesterol lowered, irrespective 
of baseline concentrations of LDL cholesterol, triglyceride, 
or HDL cholesterol.54 The use of these drugs in patients 
with hypertriglyceridaemia is justiﬁ able because of their 
proven ability to reduce cardiovascular disease. They also 
variably reduce plasma triglyceride concentrations by up to 
30%,55 with reductions dependent on baseline triglyceride 
concentration and dose of statin used. To achieve 
recommended targets, the choice of statin should be based 
on eﬃ  cacy for LDL cholesterol reduction, taking into 
account safety considerations.6,7 In hyper triglyceridaemia, 
because LDL cholesterol often cannot be established, 
achievement of non-HDL cholesterol or APOB targets 
should also be a goal of treatment.56
Fibrates
With a triglyceride-lowering eﬀ ect of 40%,57 dependent on 
baseline triglyceride concentrations, ﬁ brates are the ﬁ rst-
line treatment to decrease risk of pancreatitis for patients 
with triglyceride concentrations of more than 10 mmol/L. 
Although controversial, ﬁ ndings from a meta-analysis28 
including more than 45 000 individuals suggested that 
ﬁ brates could reduce non-fatal acute coronary events and 
revascularisation by about 9% (together with an absence 
of overall eﬀ ect for total and cardiovascular mortality and a 
non-signiﬁ cant increase in non-cardiovascular deaths), 
particularly in people with triglyceride concentrations of 
more than 2·3 mmol/L and HDL cholesterol 
concentrations of less than 1·0 mmol/L.29 Therefore, 
ﬁ brates can be used as additional therapy for individuals 
with high triglyceride and low HDL cholesterol.3 However, 
in monogenic hypertriglyceridaemia due to LPL deﬁ ciency 
and triglyceride concentrations of more than 20 mmol/L, 
ﬁ brates have little to no clinical beneﬁ t.
Nicotinic acid
Treatment with nicotinic acid (also known as niacin) at a 
dose of 2–3 g/day is associated with up to 30% reduction 
in triglyceride concentration, 20% increase in HDL 
cholesterol concentration, up to 20% lowering of LDL 
cholesterol concentration, and up to 25% reduction in 
lipoprotein(a) concentration. Findings from studies of the 
cardiovascular disease beneﬁ ts of nicotinic acid are 
conﬂ icting. The 2011 Consensus Panel recommendations 
from the European Atherosclerosis Society3 supported the 
addition of nicotinic acid to statin therapy for individuals 
not at target concentrations of LDL cholesterol or non-
HDL cholesterol, particularly if triglyceride remains high 
and HDL cholesterol is low. Combination therapy that 
includes nicotinic acid is a therapeutic option for statin-
intolerant patients. However, nicotinic acid is no longer a 
therapeutic option in Europe, because of the withdrawal 
of extended-release nicotinic acid combined with 
laropiprant after the announcement of negative results 
from the HPS-2 THRIVE study.58 Extended-release 
nicotinic acid remains available in North America under 
the trade name Niaspan. This formulation was used in the 
AIM-HIGH study,30 ﬁ ndings from which also showed no 
clinical beneﬁ t in reducing primary endpoints of death 
from coronary heart disease, non-fatal myocardial 
infarction, and ischaemic stroke.
Bile acid sequestrants
In patients with hypertriglyceridaemia, bile acid sequestrants 
can often cause a further increase in triglyceride 
concentrations, so these drugs should be used with caution 
in this patient group. Colesevelam can reduce LDL 
cholesterol concentrations by 15–20% in addition to the 
reduction achieved with statin therapy,59 and might be an 
option in the context of very mild hypertriglyceridaemia for 
individuals whose LDL cholesterol, APOB, or non-HDL 
cholesterol are not at target concentrations, or in statin-
intolerant people.
Omega-3 fatty acids
Omega-3 polyunsaturated fatty acids at doses of up to 4 g 
daily reduce triglyceride concentrations by up to 30%, 
dependent on baseline concentrations, and might 
therefore be useful for prevention of pancreatitis.4 
Findings from a meta-analysis31 showed that 
omega-3 supplementation was not signiﬁ cantly 
associated with reductions in all-cause mortality, 
myocardial infarction, or stroke.
Future research directions for 
hypertriglyceridaemia
Recent meta-analyses of gene-centric genome-wide 
association studies, and resequencing studies, have 
begun to further expand and elucidate the genetic 
underpinnings of diﬀ erent forms of hyper tri-
glyceridaemia.60 Incorporation of this knowledge into 
future exome and genome sequencing studies might 
enable identiﬁ cation of new candidate genes. For 
example, patients with hypertriglyceridaemia and 
families with a high genetic risk score could be sequenced 
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for known triglyceride loci to identify the full range of 
hypertriglyceridaemia-associated variants in these 
regions, whereas patients with hypertriglyceridaemia 
and families with a low hypertriglyceridaemia genetic 
risk score could be sequenced at the exome or genome 
level to identify new variants and genes for 
hypertriglyceridaemia.
Such approaches might oﬀ er the possibility of 
personalised medicine, in which individuals with 
hypertriglyceridaemia are assessed, diagnosed, and 
treated according to their individual genetic composition 
and molecular phenotype.60 To address the complexity of 
this task, systems approaches—integrating genomic, 
transcriptomic, proteomic, and epigenomic data with 
metabolic and clinical phenotypes—are under 
development.61 One example is weighted coexpression 
network analysis that correlates gene expression and 
methylation networks with variants and phenotypes.62 
This analysis could provide a functionally oriented 
method to identify additional new hypertriglyceridaemia-
associated genes and pathways in tissues relevant to lipid 
metabolism. However, for many individuals with 
hypertriglyceridaemia, the usual treatment options will 
probably be equally eﬀ ective, irrespective of the 
underlying combinations of predisposing alleles; this 
hypothesis needs to be formally studied.
Additionally, gene therapy is being studied in individuals 
with familial hyperchylomicronaemia. Speciﬁ cally, 
expression of a recombinant virus containing the human 
hyperfunctional LPL*S447X variant showed promise in 
animals,63 and early clinical trials in people with 
intramuscular injections of alipogene tiparvovec (an 
adeno-associated virus carrying LPL) mediated local LPL 
expression, and was associated with a transient reduction 
in plasma triglyceride concentrations.64 This treatment, 
which is also known by the trade name Glybera, was 
recently approved by the European Medicines Agency for 
the treatment of classic hyperlipoproteinaemia type 1 (LPL 
deﬁ ciency).
Finally, new treatments for hypertriglyceridaemia have 
been developed that are based on genetic studies that 
identiﬁ ed rare causative mutations in families with 
phenotypes of severely diminished triglyceride 
concentrations. For example, lomitapide, an inhibitor of 
MTTP that reduces triglyceride in addition to all APOB-
containing lipoproteins, was developed because 
individuals with homozygous mutations in MTTP 
causing abetalipoproteinaemia have depressed trigly-
ceride concentrations.65 Similarly, low triglyceride 
concentrations in other families with monogenic 
triglyceride deﬁ ciency prompted the development of new 
biological agents targeting APOB (the recently approved 
drug mipomersen),66 APOC3,67 and ANGPTL3.68
Conclusions
Diagnosis of hypertriglyceridaemia is relevant because 
even slight increases in triglyceride concentrations are 
usually associated with increased risk of cardiovascular 
disease, severely increased triglyceride is associated with 
increased risk of pancreatitis, and hyper tri glyceridaemia 
often coexists with other metabolic disturbances that are 
associated with increased cardiometabolic risk. 
Epidemiological, genetic, and clinical trial evidence has 
led us to recommend a simpliﬁ ed deﬁ nition of 
hypertriglyceridaemia (panel 1), with severe 
hypertriglyceridaemia (triglyceride concentrations of 
more than 10 mmol/L, especially in the paediatric age 
group) more likely to be related to monogenic causes, and 
mild-to-moderate hyper triglyceridaemia (triglyceride 
concentrations of 2–10 mmol/L) more likely to have a 
polygenic basis with secondary factors. The presence of 
concomitant lipid disturbances depends on additional 
genetic factors. Knowledge of the precise molecular 
defect might be helpful to guide therapy for monogenic 
hyper triglyceridaemia disorders, particularly in children 
and adolescents with severe hyper triglyceridaemia due to 
LPL deﬁ ciency and related disorders. However, in 
polygenic hypertriglyceridaemia, no evidence suggests 
that genotyping improves diagnosis or management. 
Non-fasting lipid measurements might improve the 
eﬃ  ciency of screening and diagnosis of hyper-
triglyceridaemia, whereas related variables (eg, non-HDL 
cholesterol and APOB) can provide guidance for therapy, 
especially when hypertriglyceridaemia is moderate to 
severe. The present mainstay of treatment for all types of 
hypertriglyceridaemia focuses on risk-factor control, diet, 
and lifestyle choice to ensure greatest health for 
individuals with hyper tri glyceridaemia. Pharmaco therapy 
can also be useful in selected subgroups, provided that it 
is in line with guideline recommendations. Finally, 
research in progress, both genetic and non-genetic, might 
identify new therapeutic targets that could lead to 
optimisation of clinical management in individuals with 
hypertriglyceridaemia.
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